Partner Stuart Falber recently spoke with Fierce Biotech about the need for tech, talent and innovation in the life sciences industry. Falber, who co-chairs WilmerHale’s Life Sciences Group and has counseled life sciences companies for more than 30 years, discussed how biotech companies can create value and the types of deals that are happening in the industry today.
Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.
Thank you for your interest in WilmerHale.
